001     179919
005     20240229145558.0
024 7 _ |a 10.1186/s12885-022-09589-y
|2 doi
024 7 _ |a pmid:35568802
|2 pmid
024 7 _ |a altmetric:128280427
|2 altmetric
037 _ _ |a DKFZ-2022-00968
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kohls, Mirjam
|b 0
245 _ _ |a Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study.
260 _ _ |a Heidelberg
|c 2022
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1652946410_30403
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Body mass index (BMI) and cardiometabolic comorbidities such as cardiovascular disease and type 2 diabetes have been studied as negative prognostic factors in cancer survival, but possible dependencies in the mechanisms underlying these associations remain largely unexplored. We analysed these associations in colorectal and breast cancer patients.Based on repeated BMI assessments of cancer-free participants from four European countries in the European Prospective Investigation into Cancer and nutrition (EPIC) study, individual BMI-trajectories reflecting predicted mean BMI between ages 20 to 50 years were estimated using a growth curve model. Participants with incident colorectal or breast cancer after the age of 50 years were included in the survival analysis to study the prognostic effect of mean BMI and cardiometabolic diseases (CMD) prior to cancer. CMD were defined as one or more chronic conditions among stroke, myocardial infarction, and type 2 diabetes. Hazard ratios (HRs) and confidence intervals (CIs) of mean BMI and CMD were derived using multivariable-adjusted Cox proportional hazard regression for mean BMI and CMD separately and both exposures combined, in subgroups of localised and advanced disease.In the total cohort of 159,045 participants, there were 1,045 and 1,620 eligible patients of colorectal and breast cancer. In colorectal cancer patients, a higher BMI (by 1 kg/m2) was associated with a 6% increase in risk of death (95% CI of HR: 1.02-1.10). The HR for CMD was 1.25 (95% CI: 0.97-1.61). The associations for both exposures were stronger in patients with localised colorectal cancer. In breast cancer patients, a higher BMI was associated with a 4% increase in risk of death (95% CI: 1.00-1.08). CMDs were associated with a 46% increase in risk of death (95% CI: 1.01-2.09). The estimates and CIs for BMI remained similar after adjustment for CMD and vice versa.Our results suggest that cumulative exposure to higher BMI during early to mid-adulthood was associated with poorer survival in patients with breast and colorectal cancer, independent of CMD prior to cancer diagnosis. The association between a CMD diagnosis prior to cancer and survival in patients with breast and colorectal cancer was independent of BMI.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Body mass index
|2 Other
650 _ 7 |a Breast cancer
|2 Other
650 _ 7 |a Cardiovascular disease
|2 Other
650 _ 7 |a Cohort study
|2 Other
650 _ 7 |a Colorectal cancer
|2 Other
650 _ 7 |a Comorbidity
|2 Other
650 _ 7 |a Cumulative exposure
|2 Other
650 _ 7 |a Diabetes
|2 Other
650 _ 7 |a Survival
|2 Other
700 1 _ |a Freisling, Heinz
|b 1
700 1 _ |a Charvat, Hadrien
|b 2
700 1 _ |a Soerjomataram, Isabelle
|b 3
700 1 _ |a Viallon, Vivian
|b 4
700 1 _ |a Davila-Batista, Veronica
|b 5
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 6
|u dkfz
700 1 _ |a Turzanski-Fortner, Renée
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 7
|u dkfz
700 1 _ |a Aleksandrova, Krasimira
|b 8
700 1 _ |a Schulze, Matthias B
|b 9
700 1 _ |a Dahm, Christina C
|b 10
700 1 _ |a Tilma Vistisen, Helene
|b 11
700 1 _ |a Rostgaard-Hansen, Agnetha Linn
|b 12
700 1 _ |a Tjønneland, Anne
|b 13
700 1 _ |a Bonet, Catalina
|b 14
700 1 _ |a Sánchez, Maria-Jose
|b 15
700 1 _ |a Colorado-Yohar, Sandra
|b 16
700 1 _ |a Masala, Giovanna
|b 17
700 1 _ |a Palli, Domenico
|b 18
700 1 _ |a Krogh, Vittorio
|b 19
700 1 _ |a Ricceri, Fulvio
|b 20
700 1 _ |a Rolandsson, Olov
|b 21
700 1 _ |a Lu, Sai San Moon
|b 22
700 1 _ |a Tsilidis, Konstantinos K
|b 23
700 1 _ |a Weiderpass, Elisabete
|b 24
700 1 _ |a Gunter, Marc J
|b 25
700 1 _ |a Ferrari, Pietro
|b 26
700 1 _ |a Berger, Ursula
|b 27
700 1 _ |a Arnold, Melina
|b 28
773 _ _ |a 10.1186/s12885-022-09589-y
|g Vol. 22, no. 1, p. 546
|0 PERI:(DE-600)2041352-X
|n 1
|p 546
|t BMC cancer
|v 22
|y 2022
|x 1471-2407
909 C O |o oai:inrepo02.dkfz.de:179919
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-14T16:18:36Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-14T16:18:36Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2021-02-14T16:18:36Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-19
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-19
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21